16263-54-0

Usage

Uses

Used in Pharmaceutical Industry:
3,6-Dichloro-1,2-benzisoxazole is used as a building block for the synthesis of various pharmaceutical compounds. Its unique structure and potential bioactive properties make it a valuable component in the development of new drugs and therapeutic agents.
Used in Chemical Research:
3,6-Dichloro-1,2-benzisoxazole is used as a research compound in the field of organic chemistry. Its reactivity and structural characteristics allow chemists to explore new synthetic pathways and investigate its potential applications in various chemical reactions.
Used in Agricultural Industry:
3,6-Dichloro-1,2-benzisoxazole is used as a chemical intermediate in the synthesis of agrochemicals. Its potential bioactivity and ability to be incorporated into more complex molecules make it a valuable component in the development of new pesticides and other agricultural products.
Used in Material Science:
3,6-Dichloro-1,2-benzisoxazole is used as a component in the development of new materials with specific properties. Its unique structure and potential to form stable complexes with other molecules make it a promising candidate for use in the creation of advanced materials with applications in various industries.

Upstream product

• 61977-29-5 6-chloro-benzo[d]isoxazol-3-ol 
• 61977-29-5 CBIO 
• 61799-78-8 4-chloro-N,2-dihydroxybenzamide 
• 22717-55-1 methyl 4-chloro-2-hydroxybenzoate 
• 5106-98-9 4-chlorosalicylic acid 

Downstream Products

• 1351534-32-1 (2R)-2-[4-chloro-5-[[3-(6-methoxybenzisoxazol-3-yl)-2-oxo-benzimidazol-1-yl]methyl]phenoxy]propanoic acid 
• 1351534-31-0 (2R)-2-[2-chloro-5-[[3-(6-methoxybenzisoxazol-3-yl)-2-oxo-benzimidazol-1-yl]methyl]phenoxy]propanoic acid 
• 668489-65-4 3-[1-(6-chloro-benzo[d]isoxazol-3-yl)-2-methyl-5-trifluoromethoxy-1H-indol-3-yloxy]-phenol 

Relevant academic research and scientific papers

Aralkylpiperidine (or piperazinecarboxylic) and its derivatives used for treating hypercalcemia schinzopherenia

PROBLEM TO BE SOLVED: To provide an agent for treating schizophrenia and related neuropsychiatric diseases.SOLUTION: This invention provides an aralkylpiperidine (or piperazine) derivative represented by formula (1), where A ring is a 5-7 membered heterocycle including N, with the heterocycle including a hetero atom arbitrarily selected from O, S, N; X is O, an amino group or a substituted amino group; Z is CH, N or C; Y is O, N or S; n is an integer of 1-5; and R1-R6 are H, a C1-C4 alkyl group or the like.

ARALKYL SUBSTITUTED PIPERIDINE OR PIPERAZINE DERIVATIVES AND THEIR USE FOR TREATING SCHIZOPHRENIA

The present invention discloses an aralkyl substituted piperidine or piperazine derivative and the use of the derivative in preparation of medicaments for treating schizophrenia and correlative psychoneuroses. It is shown by pharmacological tests that the derivative of the present invention has better antischizophrenic effect and less toxicity. Said derivative is a free base or salt of the compound having the following general formula.

Synthesis and Biological Evaluation of 1-(1,2-Benzisothiazol-3-yl)- and (1,2-Benzisoxazol-3-yl)piperazine Derivatives as Potential Antipsychotic Agents

Members of the series of title compounds were tested for potential antipsychotic activity in relevant receptor binding assays and behavioral screens.Structure-activity relationships within the series are discussed.Compound 24 (BMY 13859-1), a (1,2-benzisothiazol-3-yl)piperazine derivative, was selected for further study because of its potent and selective profile in primary CNS tests.It was active in the Sidman avoidance paradigm and blocked amphetamine-induced stereotyped behavior in dogs for up to 7 h.The compound's lack of typical neuroleptic-like effects in therat catalepsy test and its failure to produce dopamine receptor supersensitivity following chronic administration indicate that it should not cause the movement disorders commonly associated with antipsychotic therapy.Although 24 has potent affinity for dopaminergic binding sites, its even greater affinity for serotonin receptors suggests that a serotonergic component may be relevant to its atypical profile.Compound 24 is currently undergoing clinical evaluation in schizophrenic patients.